相关论文: Bayesian data augmentation dose finding with conti…
This paper proposes a strategy for regularized estimation in multi-way contingency tables, which are common in meta-analyses and multi-center clinical trials. Our approach is based on data augmentation, and appeals heavily to a novel class…
Biomarker-guided designs are increasingly used to evaluate personalized treatments based on patients' biomarker status in Phase II and III clinical trials. With adaptive enrichment, these designs can improve the efficiency of evaluating the…
Estimating counterfactual outcomes over time has the potential to unlock personalized healthcare by assisting decision-makers to answer ''what-iF'' questions. Existing causal inference approaches typically consider regular, discrete-time…
Computer-assisted diagnosis (CAD) based on deep learning has become a crucial diagnostic technology in the medical industry, effectively improving diagnosis accuracy. However, the scarcity of brain tumor Magnetic Resonance (MR) image…
Unmeasured confounding bias threatens the validity of observational studies. While sensitivity analyses and study designs have been proposed to address this issue, they often overlook the growing availability of auxiliary data. Using…
The success of deep learning depends heavily on the availability of large datasets, but in robotic manipulation there are many learning problems for which such datasets do not exist. Collecting these datasets is time-consuming and…
While deep AUC maximization (DAM) has shown remarkable success on imbalanced medical tasks, e.g., chest X-rays classification and skin lesions classification, it could suffer from severe overfitting when applied to small datasets due to its…
In epidemiological surveys, data missing not at random (MNAR) due to survey nonresponse may potentially lead to a bias in the risk factor estimates. We propose an approach based on Bayesian data augmentation and survival modelling to reduce…
Existing causal methods for time-varying exposure and time-varying confounding focus on estimating the average causal effect of a time-varying binary treatment on an end-of-study outcome, offering limited tools for characterizing marginal…
One common approach for dose optimization is a two-stage design, which initially conducts dose escalation to identify the maximum tolerated dose (MTD), followed by a randomization stage where patients are assigned to two or more doses to…
There is a growing interest in the estimation of the number of unseen features, mostly driven by biological applications. A recent work brought out a peculiar property of the popular completely random measures (CRMs) as prior models in…
Data augmentation (DA) methods tailored to specific domains generate synthetic samples by applying transformations that are appropriate for the characteristics of the underlying data domain, such as rotations on images and time warping on…
Data Augmentation (DA) is a technique to increase the quantity and diversity of the training data, and by that alleviate overfitting and improve generalisation. However, standard DA produces synthetic data for augmentation with limited…
Bayesian methods are a popular choice for statistical inference in small-data regimes due to the regularization effect induced by the prior. In the context of density estimation, the standard nonparametric Bayesian approach is to target the…
Although deep neural networks have made remarkable achievements in the field of automatic modulation recognition (AMR), these models often require a large amount of labeled data for training. However, in many practical scenarios, the…
Dual agent dose-finding trials study the effect of a combination of more than one agent, where the objective is to find the Maximum Tolerated Dose Combination (MTC), the combination of doses of the two agents that is associated with a…
Cancer remains a leading cause of death worldwide, necessitating personalized treatment approaches to improve outcomes. Theranostics, combining molecular-level imaging with targeted therapy, offers potential for precision oncology but…
Cost-effectiveness analyses (CEAs) compare the costs and health outcomes of treatment regimes to inform medical decisions. With observational claims data, CEAs must address nonrandom treatment assignment, administrative censoring, and…
Data-driven risk analysis involves the inference of probability distributions from measured or simulated data. In the case of a highly reliable system, such as the electricity grid, the amount of relevant data is often exceedingly limited,…
The commonplace description of phase 1 clinical trials in oncology as "primarily concerned with safety" is belied by their near universal adoption of dose-escalation practices which are inherently unsafe. In contrast with dose titration,…